In other company news, Merck (MRK) reported higher fiscal Q3 results and raised its full-year financial guidance. MRK shares gained 2% in premarket trading. Rafael Holdings (RFL) slumped by 78% after saying that the late-stage trial of CPI-613 combined with modified Folfirinox in patients with metastatic adenocarcinoma of the pancreas did not meet its primary endpoint of overall survival.